Skip to main content
Contact Us
Subscribe
E-Edition
80°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
160.29
-0.21 (-0.13%)
Official Closing Price
Updated: 4:10 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Johnson & Johnson
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
99
100
Next >
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
January 23, 2024
From
Johnson & Johnson
Via
Business Wire
2 Genius Safe Stocks to Buy for 2024 and Beyond
January 23, 2024
These companies have considerable profits and tried-and-true dividends in common.
Via
The Motley Fool
Earnings Scheduled For January 23, 2024
January 23, 2024
Companies Reporting Before The Bell • Webster Finl (NYSE:WBS) is estimated to report quarterly earnings at $1.46 per share on revenue of $603.11 million.
Via
Benzinga
How Is The Market Feeling About Johnson & Johnson?
January 19, 2024
Via
Benzinga
3 Dividend Stocks For A Steady Drip Of Income
January 18, 2024
Dividend Reinvestment Plans allow investors to unleash the power of compounding dividends.
Via
Talk Markets
Fear & Greed Index Remains In 'Greed' Zone; Dow Settles Above 38,000
January 23, 2024
The CNN Money Fear and Greed index remained in the "Greed" zone on Monday. U.S. stocks closed higher on Monday, with the Dow Jones index settling above the 38,000 mark for the first time.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Verizon, Netflix And 3 Stocks To Watch Heading Into Tuesday
January 23, 2024
With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Dow Jones Stocks: From 3M To Intel, A Big Earnings Week For Blue Chips
January 22, 2024
Eight Dow Jones stock report earnings this week. Several, including Verizon and 3M, are in buy zones or near buy points.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
Via
Benzinga
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
January 16, 2024
Via
Benzinga
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?
January 22, 2024
US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
January 22, 2024
FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic...
Via
Benzinga
Exposures
Product Safety
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
January 22, 2024
Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
3 undervalued stocks: Is now the right time to buy?
January 22, 2024
WK Kellogg, Newmont, and WEC Energy Group have upside potential as undervalued stocks, although each is navigating challenges that pushed valuations lower.
Via
MarketBeat
I'm Putting My Cash Stockpile to Work on These 3 Stocks
January 21, 2024
With the market selling off to start the year, this Fool plans to put some of his growing cash pile to work.
Via
The Motley Fool
Nearing Retirement? These Stocks Are as Safe as They Come
January 21, 2024
These stocks should provide solid income with little drama.
Via
The Motley Fool
Tesla, Netflix, Intel Take Center Stage In Pivotal Q4 Earnings Week As S&P 500 Eyes Breaking New Highs
January 22, 2024
According to Factset, the fourth-quarter earnings season has had a weak start, with the percentage of S&P 500 companies reporting positive earnings surprises below average.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Walgreens Boots Alliance Just Cut Its Dividend: Here Are 2 Companies That Won't
January 21, 2024
Not every dividend stock is created equal, and these two far exceed Walgreens Boots Alliance.
Via
The Motley Fool
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
January 21, 2024
These stocks may help you win in 2024 -- no matter what the market does.
Via
The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
January 20, 2024
These big winners could keep the momentum going.
Via
The Motley Fool
Q4 Earnings Results Reflect Stability
January 19, 2024
We get into the heart of the Q4 earnings season this week, with more than 225 companies reporting results, including 71 S&P 500 members from various sectors and industries
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
3 Reasons to Rely on Dividend Stocks
January 18, 2024
Dividend stocks can be a great hedge against volatile while still providing powerful returns via compounding.
Via
InvestorPlace
7 Must-Have Stocks for Serious Wealth Accumulation
January 18, 2024
Unlock the strategies of seven finance and commerce stalwarts on the path to serious wealth accumulation and industry leadership.
Via
InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
The 3 Most Undervalued Value Stocks to Buy in January
January 15, 2024
With so many investments turning in a surprisingly robust performance last year, it’s time to consider undervalued value stocks.
Via
InvestorPlace
4 Fantastic Dividend King Stocks to Buy in 2024
January 15, 2024
All four of these companies have been increasing their dividend payouts for over 50 years.
Via
The Motley Fool
Hidden High-Yielders: 7 Overlooked Stocks with Attractive Dividends
January 14, 2024
Here are seven overlooked high-yield dividend stocks for you to consider no matter where interest rates at the end of 2024.
Via
InvestorPlace
2 Former Warren Buffett Stocks That Stand Out as Stong Buys in 2024
January 14, 2024
Berkshire Hathaway exited its positions in these two blue chip dividend stocks last year, but they are still superb buys for certain types of investors.
Via
The Motley Fool
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
2 Average Stocks That Could Make You Rich
January 13, 2024
You don't always have to pick a game-changing company to win in the stock market.
Via
The Motley Fool
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.